artificial intelligenceOrakl takes on four Sanofi cancer assetsFrench techbio Orakl Oncology has secured exclusive rights to four undisclosed oncology assets from Sanofi, giving the startup an opportunity to test whether its combination of patient-derived tumour … more ➔
M&AMission Therapeutics refocuses on CNS and sells $292M kidney drug to DimerixUK biotech Mission Therapeutics has sold its Phase 2-ready acute kidney injury drug MTX652 to Australia’s Dimerix in a deal worth up to $292 million (€254.7 million), freeing Mission to concentrate … more ➔
M&ALilly buys Europe-rooted AtaiBeckley for up to $3.8BEli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German and British roots into one of the sector’s largest pharmaceutical … more ➔
intellectual propertySanofi joins the mRNA vaccine patent warsSanofi has sued Pfizer and Moderna, alleging that their COVID-19 and respiratory syncytial virus (RSV) vaccines infringe patents covering the delivery of messenger RNA using lipid nanoparticles it acquired … more ➔
licensingAstraZeneca reunites with Dizal in $1.5bn lung cancer dealAstraZeneca has agreed to pay up to $1.5bn for global rights to Zegfrovy, an EGFR-targeted lung cancer drug developed by Dizal Pharmaceutical – the Chinese biotech it helped create nearly a decade … more ➔
Bayer AGBayerBayer rebuilds pharma while waiting for Monsanto reliefA stronger pipeline and new financing give Bayer room to manoeuvre — but investors are still watching one issue: the US glyphosate litigation. more ➔
Wuxi AppTecChinaWuXi AppTec bets on expansion in EuropeGlobal science, local innovation: In an interview with European Biotech Magazine, WuXi AppTec Co-CEO Steve Yang explains why Europe remains a key source of scientific innovation, why the company continues … more ➔
fundraisingDraig raises $65M Series B as depression trials advanceWelsh biotech Draig Therapeutics has raised an oversubscribed $65 million Series B to accelerate its neuropsychiatry pipeline, taking its total funding to $205 million little more than a year after emerging … more ➔
investmentCriteriaCaixa targets €300M for biotech and tech by 2030Spanish investment holding company CriteriaCaixa plans to invest €300m in early-stage biotechnology and technology companies by 2030 through its two specialist venture funds. more ➔
TechnologyTargeted Protein Degradation: Designed to destroyTargeted protein degradation (TPD) has moved from a highly experimental concept to one of the most closely watched modalities in biopharma. What began with first-generation PROTACs (proteolysis-targeting … more ➔
Bayer AG
Wuxi AppTec
